COVID-19 vaccination in autoimmune disease (COVAD) survey protocol

Parikshit Sen; Latika Gupta; James B. Lilleker; Vishwesh Aggarwal; Sinan Kardes; Marcin Milchert; Tamer Gheita; Babur Salim; Tsvetelina Velikova; Abraham Edgar Gracia-Ramos; Ioannis Parodis; Albert Selva O'Callaghan; Elena Nikiphorou; Ai Lyn Tan; Lorenzo Cavagna; Miguel A. Saavedra; Samuel Katsuyuki Shinjo; Nelly Ziade; Johannes Knitza; Masataka Kuwana; Giovanni Cagnotto; Arvind Nune; Oliver Distler; Hector Chinoy; Vikas Aggarwal; Rohit Aggarwal; COVAD Study Group

doi:10.1007/s00296-021-05046-4

COVID-19 vaccination in autoimmune disease (COVAD) survey protocol

Parikshit Sen, Latika Gupta, James B. Lilleker, Vishwesh Aggarwal, Sinan Kardes, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Albert Selva O'Callaghan, Elena Nikiphorou, Ai Lyn Tan, Lorenzo Cavagna, Miguel A. Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Masataka KuwanaGiovanni Cagnotto, Arvind Nune, Oliver Distler, Hector Chinoy, Vikas Aggarwal, Rohit Aggarwal, COVAD Study Group

Reumatologi

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

1 Citering (SciVal)

Sammanfattning

The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.

Originalspråk	engelska
Sidor (från-till)	23-29
Antal sidor	7
Tidskrift	Rheumatology International
Volym	42
Utgåva	1
DOI	https://doi.org/10.1007/s00296-021-05046-4
Status	Published - 2022

Ämnesklassifikation (UKÄ)

Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi

Tillgång till dokument

10.1007/s00296-021-05046-4

Citera det här

Sen, P., Gupta, L., Lilleker, J. B., Aggarwal, V., Kardes, S., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., O'Callaghan, A. S., Nikiphorou, E., Tan, A. L., Cavagna, L., Saavedra, M. A., Shinjo, S. K., Ziade, N., Knitza, J., ... COVAD Study Group (2022). COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatology International, 42(1), 23-29. https://doi.org/10.1007/s00296-021-05046-4

Sen, Parikshit ; Gupta, Latika ; Lilleker, James B. ; Aggarwal, Vishwesh ; Kardes, Sinan ; Milchert, Marcin ; Gheita, Tamer ; Salim, Babur ; Velikova, Tsvetelina ; Gracia-Ramos, Abraham Edgar ; Parodis, Ioannis ; O'Callaghan, Albert Selva ; Nikiphorou, Elena ; Tan, Ai Lyn ; Cavagna, Lorenzo ; Saavedra, Miguel A. ; Shinjo, Samuel Katsuyuki ; Ziade, Nelly ; Knitza, Johannes ; Kuwana, Masataka ; Cagnotto, Giovanni ; Nune, Arvind ; Distler, Oliver ; Chinoy, Hector ; Aggarwal, Vikas ; Aggarwal, Rohit ; COVAD Study Group. / COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. I: Rheumatology International. 2022 ; Vol. 42, Nr. 1. s. 23-29.

@article{d52e927eb8d64b6eacab744b9cae50ad,

title = "COVID-19 vaccination in autoimmune disease (COVAD) survey protocol",

abstract = "The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.",

keywords = "Autoimmune diseases, COVAD, COVID-19, Survey, Vaccination",

author = "Parikshit Sen and Latika Gupta and Lilleker, {James B.} and Vishwesh Aggarwal and Sinan Kardes and Marcin Milchert and Tamer Gheita and Babur Salim and Tsvetelina Velikova and Gracia-Ramos, {Abraham Edgar} and Ioannis Parodis and O'Callaghan, {Albert Selva} and Elena Nikiphorou and Tan, {Ai Lyn} and Lorenzo Cavagna and Saavedra, {Miguel A.} and Shinjo, {Samuel Katsuyuki} and Nelly Ziade and Johannes Knitza and Masataka Kuwana and Giovanni Cagnotto and Arvind Nune and Oliver Distler and Hector Chinoy and Vikas Aggarwal and Rohit Aggarwal and {COVAD Study Group}",

year = "2022",

doi = "10.1007/s00296-021-05046-4",

language = "English",

volume = "42",

pages = "23--29",

journal = "Rheumatology International",

issn = "1437-160X",

publisher = "Springer",

number = "1",

}

Sen, P, Gupta, L, Lilleker, JB, Aggarwal, V, Kardes, S, Milchert, M, Gheita, T, Salim, B, Velikova, T, Gracia-Ramos, AE, Parodis, I, O'Callaghan, AS, Nikiphorou, E, Tan, AL, Cavagna, L, Saavedra, MA, Shinjo, SK, Ziade, N, Knitza, J, Kuwana, M, Cagnotto, G, Nune, A, Distler, O, Chinoy, H, Aggarwal, V, Aggarwal, R & COVAD Study Group 2022, 'COVID-19 vaccination in autoimmune disease (COVAD) survey protocol', Rheumatology International, vol. 42, nr. 1, s. 23-29. https://doi.org/10.1007/s00296-021-05046-4

COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. / Sen, Parikshit; Gupta, Latika; Lilleker, James B.; Aggarwal, Vishwesh; Kardes, Sinan; Milchert, Marcin; Gheita, Tamer; Salim, Babur; Velikova, Tsvetelina; Gracia-Ramos, Abraham Edgar; Parodis, Ioannis; O'Callaghan, Albert Selva; Nikiphorou, Elena; Tan, Ai Lyn; Cavagna, Lorenzo; Saavedra, Miguel A.; Shinjo, Samuel Katsuyuki; Ziade, Nelly; Knitza, Johannes; Kuwana, Masataka; Cagnotto, Giovanni; Nune, Arvind; Distler, Oliver; Chinoy, Hector; Aggarwal, Vikas; Aggarwal, Rohit; COVAD Study Group.

I: Rheumatology International, Vol. 42, Nr. 1, 2022, s. 23-29.

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

TY - JOUR

T1 - COVID-19 vaccination in autoimmune disease (COVAD) survey protocol

AU - Sen, Parikshit

AU - Gupta, Latika

AU - Lilleker, James B.

AU - Aggarwal, Vishwesh

AU - Kardes, Sinan

AU - Milchert, Marcin

AU - Gheita, Tamer

AU - Salim, Babur

AU - Velikova, Tsvetelina

AU - Gracia-Ramos, Abraham Edgar

AU - Parodis, Ioannis

AU - O'Callaghan, Albert Selva

AU - Nikiphorou, Elena

AU - Tan, Ai Lyn

AU - Cavagna, Lorenzo

AU - Saavedra, Miguel A.

AU - Shinjo, Samuel Katsuyuki

AU - Ziade, Nelly

AU - Knitza, Johannes

AU - Kuwana, Masataka

AU - Cagnotto, Giovanni

AU - Nune, Arvind

AU - Distler, Oliver

AU - Chinoy, Hector

AU - Aggarwal, Vikas

AU - Aggarwal, Rohit

AU - COVAD Study Group

PY - 2022

Y1 - 2022

N2 - The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.

AB - The coronavirus disease-2019 (COVID-19) pandemic continues to be a cause of unprecedented global morbidity and mortality. Whilst COVID-19 vaccination has emerged as the only tangible solution to reducing poor clinical outcomes, vaccine hesitancy continues to be an obstacle to achieving high levels of vaccine uptake. This represents particular risk to patients with autoimmune diseases, a group already at increased risk of hospitalization and poor clinical outcomes related to COVID-19 infection. Whilst there is a paucity of long-term safety and efficacy data of COVID-19 vaccination in patients with autoimmune diseases, the current evidence strongly suggests that the benefits of vaccination outweigh the risks of adverse effects and disease flares. Herein, we report the protocol of the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study, an ongoing international collaborative study involving 29 countries and over 110 investigators.

KW - Autoimmune diseases

KW - COVAD

KW - COVID-19

KW - Survey

KW - Vaccination

U2 - 10.1007/s00296-021-05046-4

DO - 10.1007/s00296-021-05046-4

M3 - Article

C2 - 34779868

AN - SCOPUS:85123651276

VL - 42

SP - 23

EP - 29

JO - Rheumatology International

JF - Rheumatology International

SN - 1437-160X

IS - 1

ER -

COVID-19 vaccination in autoimmune disease (COVAD) survey protocol

Sammanfattning

Ämnesklassifikation (UKÄ)

Tillgång till dokument

Fingeravtryck

Citera det här